- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cancer center spins off diagnostic company
The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients.
The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients. The spin-off company, called Delphinus Medical Technologies, is dedicated to developing SoftVue as a commercial product. Clinical research has been conducted under an investigational device exemption from the FDA. The company is currently pursuing FDA approval to sell products based on the technology in the U.S. More than 300 women have been studied in initial clinical trials, which the company says has confirmed SoftVue as safe and accurate in identifying breast cancer.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
